Pharmacologic management of arrhythmias.
The role of antiarrhythmic drugs in the management of children with arrhythmias has changed due to the rapid development of radiofrequency ablation. Moreover, the release of new drugs and a better insight into the electrophysiologic mechanisms of arrhythmias have changed former patterns of drug management. However, because of lack of controlled trials, arrhythmia management in pediatrics is still mainly based on clinical studies and individual experience. Within these limitations, I attempt to give practical recommendations for the management of the different arrhythmias seen in children based on the latest developments in this area.
Bink-Boelkens
M T
MT
Division of Pediatric Cardiology, University Hospital, P.O. Box 30001, 9700 RB Groningen, The Netherlands.
D000241:Adenosine / Q000494:pharmacology / Q000627:therapeutic use; D000638:Amiodarone / Q000494:pharmacology / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000145:classification / Q000188:drug therapy*; D001282:Atrial Flutter / Q000188:drug therapy; D002648:Child; D004347:Drug Interactions; D006801:Humans; D011405:Propafenone / Q000494:pharmacology / Q000627:therapeutic use; D013015:Sotalol / Q000494:pharmacology / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D017180:Tachycardia, Ventricular / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D013449:Sulfonamides; C067192:ibutilide; D011405:Propafenone; D013015:Sotalol; D000241:Adenosine; D000638:Amiodarone